Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic Malignancies

Video
Conference|Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (SGO)

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.

CancerNetwork® sat down with Ronnie Shapira-Frommer, MD, to discuss research that was presented at the Society of Gynecological Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer.

Shapira-Frommer discussed multidisciplinary care in the treatment of various gynecologic malignancies and how the data at the meeting facilitate this approach.

Transcription:

We have to face patients’ cancer as a multidisciplinary team with the strength of each expertise, including surgical, radiotherapy, and medical oncologist joined together. This is unique for this field of treatment. Pushing forward with the preclinical studies and with the data [from the SGO Annual Meeting], we can move forward patient care in the best of their interest, and for us as well.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content
Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

BMS-986279 Shows Feasibility as Non-Invasive fuc-GM1 Assessment in ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Tumor penetration of atigotatug in fuc-GM1-positive lung, liver, and bone lesions was observed in those with extensive-stage small cell lung cancer.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

225AC-3BP-3940 Is Safe, Shows Activity in Heavily Pretreated Advanced Breast Cancer

Gina Mauro
June 24th 2025
Article

Retrospective analysis at SNMMI 2025 revealed α-FRT with 225AC-3BP-3940 was well tolerated and elicited responses in pretreated metastatic breast cancer.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

The use of 68Ga-Pentixafor compliments fluorodeoxyglucose and had no correlation with CXCR4 immunohistochemistry.

CXCR4 Expression in Gynecologic Malignancies Correlates With OS

Roman Fabbricatore
June 23rd 2025
Article

The use of 68Ga pentixafor complements fluorodeoxyglucose and had no correlation with CXCR4 immunohistochemistry.

A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.

Radioligand Therapy Retreatment Shows Promise in Metastatic CRPC

Tim Cortese
June 23rd 2025
Article

Results from a retrospective study show that 177Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.